Ipatasertib is an ATP-competitive small molecule pan-AKT inhibitor (AKT1, AKT2, and AKT3)21, and clinical proof of concept has been confirmed in a phase II clinical trial in which ipatasertib significantly improved progression-free survival (PFS) compared with placebo when combined with paclitaxel in patients with advanced triple negative breast cancers with PIK3CA mutation or PTEN loss22. The gene discussed is AKT1; the disease is triple-negative breast carcinoma.